Annotation Detail for NAALADL2

Basic Information
Top
| Desease Name |
|---|
| IMMUNE |
| kawasaki disease |
| Desease Name |
|---|
| Kawasaki disease |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| C116926 |
rofecoxib |
rofecoxib results in decreased expression of NAALADL2 mRNA | decreases expression | 17070997
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D001169 |
Arthritis, Experimental |
|
rofecoxib |
4.64 | 16690336 |
| MESH:D003110 |
Colonic Neoplasms |
|
rofecoxib |
3.36 | 12902858 |
| MESH:D004715 |
Endometriosis |
|
rofecoxib |
5.43 | 15652904 |
| MESH:D007410 |
Intestinal Diseases |
|
rofecoxib |
5.94 | 15831440 |
| MESH:D007417 |
Intestinal Polyps |
|
rofecoxib |
6.07 | 11245490 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
rofecoxib |
3.08 | 17565644 |
| MESH:D010003 |
Osteoarthritis |
|
rofecoxib |
4.66 | 16690336 |
| MESH:D010149 |
Pain, Postoperative |
|
rofecoxib |
6.80 | 18165598 16678543 |
PharmGKB Accession:PA142671295
| Releated disease ID |
Related disease Name |
| PA444977 | Mucocutaneous Lymph Node Syndrome |